News | Proton Therapy | August 06, 2019

IBA Signs Contract to Install Proton Therapy Center in Kansas

Construction to host IBA’s Proteus One system expected to start later this year

IBA Signs Contract to Install Proton Therapy Center in Kansas

August 6, 2019 — IBA (Ion Beam Applications S.A.) recently signed a contract and received the first payment for a Proteus One solution with The University of Kansas Health System. The contract includes a plan for a possible extension with a second ProteusOne unit in the future. The proton therapy center will be built at the Main Campus of The University of Kansas Health System in Kansas City, Kansas. Construction is anticipated to begin later this year.

The contract includes a long-term operation and maintenance agreement and the typical end-user price for a Proteus One solution, with a maintenance contract between EUR 35 and 40 million. IBA will begin to recognize revenue for the contract in the 2019 financial year.

Bob Page, president and chief executive officer  of The University of Kansas Health System commented, “We are excited to partner with IBA, the world’s leading proton therapy system provider, to bring proton therapy to Kansas City and the region. IBA’s Proteus One represents one of the most advanced solutions to delivering proton therapy. With the first system in place, and the ability to add a second system in the future, patients will be able to stay closer to home to receive the most advanced cancer care available.”

Proteus One is the compact intensity modulated proton therapy (IMPT) solution from IBA, benefiting from the latest technologies. The system is smaller, more affordable, easier to install and to operate.

For more information: www.iba-worldwide.com

Related Content

News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
Research finds that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening

Getty Images

News | Lung Imaging | May 05, 2021
May 5, 2021 — Lung cancer is the third most common cance
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
Despite receiving high radiation doses to their tumors, lung cancer patients treated with technique that spares a large part of the esophagus did not develop severe inflammation of the esophagus

Getty Images

News | Lung Imaging | April 30, 2021
April 30, 2021 — For many patients with localized lung cance...
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021
April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate canc
A 63-year-old multiple #myeloma patient, with skeletal pain. New #FDG avid axillary #lymphadenopathy 62 days (9 weeks) after second #mRNA #vaccination dose. Image used with permission of the Radiological Society of North America (#RSNA)

A 63-year-old multiple myeloma patient, with skeletal pain. New FDG avid axillary lymphadenopathy 62 days (9 weeks) after second mRNA vaccination dose. Image used with permission of the Radiological Society of North America (RSNA)

Feature | Coronavirus (COVID-19) | April 29, 2021 | By Melinda Taschetta-Millane
A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors can also be safely used for treating patients with multiple metastases.

Image courtesy of Accuray

News | Stereotactic Body Radiation Therapy (SBRT) | April 23, 2021
April 23, 2021 — A phase 1 clinical trial led by investigators at the...
A Norwegian study for the first time reveals benefit of the #PARP inhibitor #Olaparib in patients with early #breastcancer not harboring germline mutations

Getty Images

News | Radiation Therapy | April 22, 2021
April 22, 2021 — Targeted therapy in early stages of breas...